skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy

Abstract

Purpose: To examine how tumor characteristics and dose affect cataract development after plaque radiation therapy. Methods and Materials: Three hundred and eighty-four patients were diagnosed with uveal melanoma and treated with palladium-103 ({sup 103}Pd) plaque radiation therapy. Of these, 282 (74%) inclusion met exclusion criteria for follow-up time, tumor location, and phakic status. Then patient-, ophthalmic-, and radiation-specific factors (patient age, diabetes, hypertension, tumor location, tumor dimensions, and lens dose) were examined (by a Cox proportional regression model) as predictors for the development of radiation-related cataract. Results: Radiation cataract developed in 76 (24%) of patients at a mean follow-up of 39.8 months (range, 1-192). Patients with anteriorly located tumors were noted to have a higher incidence of cataract at 43.0% (43 of 100 patients) vs. 18.1% (33 cataracts per 182 patients) for posteriorly located tumors (p <0.0001). However, multivariate Cox proportional modeling showed that increasing patient age at time of treatment (p for trend = 0.0003) and higher lens dose (p for trend = 0.001) were the best predictors (biomarkers) for radiation cataract. Conclusions: Although anterior tumor location, greater tumor height, and increased patient age (at treatment) were associated with significantly greater risk for radiation cataract, dose to lens wasmore » the most significant factor.« less

Authors:
 [1];  [2];  [1];  [3];  [1];  [2]
  1. New York Eye Cancer Center, New York, NY (United States)
  2. (United States)
  3. New York Eye and Ear Infirmary, New York, NY (United States)
Publication Date:
OSTI Identifier:
21587573
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 80; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2010.02.051; PII: S0360-3016(10)00407-4; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOLOGICAL MARKERS; CATARACTS; HAZARDS; HYPERTENSION; MELANOMAS; MULTIVARIATE ANALYSIS; PALLADIUM 103; RADIATION DOSES; RADIOTHERAPY; BETA DECAY RADIOISOTOPES; CARCINOMAS; CARDIOVASCULAR DISEASES; DAYS LIVING RADIOISOTOPES; DISEASES; DOSES; ELECTRON CAPTURE RADIOISOTOPES; EPITHELIOMAS; EVEN-ODD NUCLEI; INTERMEDIATE MASS NUCLEI; ISOTOPES; MATHEMATICS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; PALLADIUM ISOTOPES; RADIOISOTOPES; RADIOLOGY; SENSE ORGANS DISEASES; STATISTICS; SYMPTOMS; THERAPY; VASCULAR DISEASES

Citation Formats

Finger, Paul T., E-mail: pfinger@eyecancer.com, New York Eye and Ear Infirmary, New York, NY, Chin, Kimberly J., Yu Guopei, Patel, Neil S., and New York Eye and Ear Infirmary, New York, NY. Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy. United States: N. p., 2011. Web. doi:10.1016/j.ijrobp.2010.02.051.
Finger, Paul T., E-mail: pfinger@eyecancer.com, New York Eye and Ear Infirmary, New York, NY, Chin, Kimberly J., Yu Guopei, Patel, Neil S., & New York Eye and Ear Infirmary, New York, NY. Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy. United States. doi:10.1016/j.ijrobp.2010.02.051.
Finger, Paul T., E-mail: pfinger@eyecancer.com, New York Eye and Ear Infirmary, New York, NY, Chin, Kimberly J., Yu Guopei, Patel, Neil S., and New York Eye and Ear Infirmary, New York, NY. Fri . "Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy". United States. doi:10.1016/j.ijrobp.2010.02.051.
@article{osti_21587573,
title = {Risk Factors for Cataract After Palladium-103 Ophthalmic Plaque Radiation Therapy},
author = {Finger, Paul T., E-mail: pfinger@eyecancer.com and New York Eye and Ear Infirmary, New York, NY and Chin, Kimberly J. and Yu Guopei and Patel, Neil S. and New York Eye and Ear Infirmary, New York, NY},
abstractNote = {Purpose: To examine how tumor characteristics and dose affect cataract development after plaque radiation therapy. Methods and Materials: Three hundred and eighty-four patients were diagnosed with uveal melanoma and treated with palladium-103 ({sup 103}Pd) plaque radiation therapy. Of these, 282 (74%) inclusion met exclusion criteria for follow-up time, tumor location, and phakic status. Then patient-, ophthalmic-, and radiation-specific factors (patient age, diabetes, hypertension, tumor location, tumor dimensions, and lens dose) were examined (by a Cox proportional regression model) as predictors for the development of radiation-related cataract. Results: Radiation cataract developed in 76 (24%) of patients at a mean follow-up of 39.8 months (range, 1-192). Patients with anteriorly located tumors were noted to have a higher incidence of cataract at 43.0% (43 of 100 patients) vs. 18.1% (33 cataracts per 182 patients) for posteriorly located tumors (p <0.0001). However, multivariate Cox proportional modeling showed that increasing patient age at time of treatment (p for trend = 0.0003) and higher lens dose (p for trend = 0.001) were the best predictors (biomarkers) for radiation cataract. Conclusions: Although anterior tumor location, greater tumor height, and increased patient age (at treatment) were associated with significantly greater risk for radiation cataract, dose to lens was the most significant factor.},
doi = {10.1016/j.ijrobp.2010.02.051},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 3,
volume = 80,
place = {United States},
year = {Fri Jul 01 00:00:00 EDT 2011},
month = {Fri Jul 01 00:00:00 EDT 2011}
}